Abstract
Importance Few studies have measured the effect of genetic factors on dementia and cognitive decline in a population of healthy older individuals followed prospectively.
Objective To examine the effect of Apolipoprotein E (APOE) genotypes and a polygenic risk score (PRS) on incident dementia and cognitive decline in a longitudinal cohort of healthy older people.
Design, Setting and Participants Post-hoc genetic analysis of a randomized clinical trial population - the ASPirin in Reducing Events in the Elderly (ASPREE) trial. At enrollment, participants had no history of diagnosed dementia, atherothrombotic cardiovascular disease, or permanent physical disability and were without cognitive impairment.
Main Outcomes and Measures Dementia (adjudicated trial endpoint) and cognitive decline, defined as a >1.5 standard deviation decline in test score for either global cognition, episodic memory, language/executive function or psychomotor speed, versus baseline scores. Cumulative incidence curves for all-cause dementia and cognitive decline were calculated with mortality as a competing event, stratified by APOE genotypes and tertiles of a PRS based on 23 common non-APOE variants.
Results 12,978 participants with European ancestry were included; 54.8% were female, and average age at baseline was 75 years (range 70 to 96). During a median 4.5 years of follow-up, 324 (2.5%) participants developed dementia and 503 (3.8%) died. Cumulative incidence of dementia to age 85 years was estimated to be 7.4% in all participants, 12.6% in APOE ε4 heterozygotes, 26.6% in ε4 homozygotes, 9.6% in the high PRS tertile, and 7.3% in the low PRS tertile. APOE ε4 heterozygosity/homozygosity was associated with a 2.5/6.3-fold increased risk of dementia and a 1.4/1.8-fold increased risk of cognitive decline, versus ε3/ε3 (P<0.001 for both). A high PRS (top tertile) was associated with a 1.4-fold increase risk of dementia, versus the low tertile (CI 1.04-1.76, P=0.02), but was not associated with cognitive decline risk (CI 0.96-1.22, P = 0.18).
Conclusions and Relevance Incidence of dementia among healthy older individuals is low across all genotypes; however, APOE ε4 and high PRS increase relative risk. APOE ε4 is associated with cognitive decline, but PRS is not.
Question How do genetic factors influence the risk of dementia and cognitive decline among healthy older individuals?
Findings We studied cumulative incidence of dementia and cognitive decline in 12,978 healthy older individuals without cardiovascular disease or cognitive impairment at enrollment, stratified by APOE genotype and a polygenic risk score (PRS). APOE ε4 and PRS increased the relative risk of dementia, but cumulative incidence was low across all genotypes. APOE genotypes were associated with cognitive decline, but PRS was not.
Meaning Incidence of dementia is low among healthy older individuals; however, genetic factors still increase relative risk.
Competing Interest Statement
Dr. Shah serves as a non-compensated member of the Board of Directors of the Alzheimers Association Illinois Chapter. His institution Rush University Medical Center receives funds for his role as Site Principal Investigator or Site Sub-Investigator for industry sponsored clinical trials and research studies involving Alzheimers disease and dementia sponsored by Amylyx Pharmaceuticals Inc. Eli Lilly & Co. Inc. Genentech Inc. Merck & Co. Inc. Navidea Biopharmaceuticals and Novartis Pharmaceutical Inc. Dr Sebra serves as Vice President of Technology Development at Sema4. Dr Schadt serves as Chief Executive Officer at Sema4. Dr Goate has consulted for Biogen AbbVie GSK Eisai and Denali Therapeutics. No other conflicts were reported.
Funding Statement
The ASPREE Healthy Ageing Biobank was supported by a Flagship cluster (including the Commonwealth Scientific and Industrial Research Organisation Monash University Menzies Research InstituteAustralian National University University of Melbourne) Monash University and the National Cancer Institute at the National Institutes of Health (supplement to U01AG029824). The ASPREE clinical trial was supported by the National Institute on Aging and the National Cancer Institute at the National Institutes of Health (U01AG029824). the National Health and Medical Research Council (NHMRC) of Australia (334047 and 1127060) Monash University and the Victorian Cancer Agency. We thank the trial staff in Australia and the US the participants who volunteered for this trial and the general practitioners and staff of the medical clinics who cared for the participants. We also thank the UK Biobank participants and admin staff. P.L is supported by a National Heart Foundation Future Leader Fellowship (102604).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent for genetic analysis was obtained with ethical approval from the Alfred Hospital Human Research Ethics Committee (390/15) and site-specific Institutional Review Boards (US).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Contact senior author of the paper for data availability
ABBREVIATIONS
- AD
- Alzheimer’s disease
- APOE
- Apolipoprotein E
- ASPREE
- ASPirin in Reducing Events in the Elderly
- GWAS
- Genome-wide association study
- PRS
- Polygenic risk score
- HWE
- Hardy-Weinberg equilibrium
- CID
- Cumulative incidence of dementia
